mTOR inhibitors: Temsirolimus and everolimus in the treatment of renal cell ... - UroToday PDF Print
UroTodayTemsirolimus has shown in a randomized phase III trial for patients with poor risk feature of metastatic renal cell carcinoma, a significant gain in overall

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.